GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lumos Pharma Inc (FRA:4NX1) » Definitions » Accumulated other comprehensive income (loss)

Lumos Pharma (FRA:4NX1) Accumulated other comprehensive income (loss) : €0.00 Mil (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Lumos Pharma Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Lumos Pharma's Accumulated other comprehensive income (loss) for the quarter that ended in Mar. 2024 was €0.00 Mil.

Lumos Pharma's quarterly Accumulated other comprehensive income (loss) increased from Sep. 2023 (€-0.00 Mil) to Dec. 2023 (€0.00 Mil) but then stayed the same from Dec. 2023 (€0.00 Mil) to Mar. 2024 (€0.00 Mil).

Lumos Pharma's annual Accumulated other comprehensive income (loss) declined from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€-0.01 Mil) but then increased from Dec. 2022 (€-0.01 Mil) to Dec. 2023 (€0.00 Mil).

Lumos Pharma Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Lumos Pharma's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumos Pharma Accumulated other comprehensive income (loss) Chart

Lumos Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accumulated other comprehensive income (loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -0.01 -

Lumos Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Accumulated other comprehensive income (loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 - - -

Lumos Pharma Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Lumos Pharma Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Lumos Pharma's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Lumos Pharma (FRA:4NX1) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lumos Pharma Inc (FRA:4NX1) » Definitions » Accumulated other comprehensive income (loss)
Comparable Companies
NLTX SIOX LTRN NERV UBX MTEM INAB ALGS NRXP MAIA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
LUMO:USA
Address
4200 Marathon Boulevard, Suite 200, Austin, TX, USA, 78756
Website
https://www.lumos-pharma.com
Lumos Pharma Inc is a biopharmaceutical company that develops treatments for cancer and rare diseases. It carries out both clinical-stage and preclinical research on a range of molecules that help the immune system fight off cancer cells. The treatments are available orally and can be used in conjunction with other cancer therapies. The company also researches an Ebola vaccine. Lumos contracts with manufacturing organizations to make their treatments, engages in partnerships with pharmaceutical companies, and operates primarily in the United States.

Lumos Pharma (FRA:4NX1) Headlines

No Headlines